Evidence map›Paper›PMID 28503723›Full record

SynthesisBreast cancer research and treatment2017

Risk of death from cardiovascular disease following breast cancer: a systematic review.

S A M Gernaat, P J Ho, N Rijnberg, M J Emaus, L M Baak, M Hartman, D E Grobbee, H M Verkooijen

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 7 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 7 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. A Systematic Review of Cardiovascular Health Among Cancer Survivors.International journal of environmental research and public health · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Trial
  12. Review
  13. Article
  14. Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

S A M GernaatDepartment of Epidemiology, University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3584 CX, Utrecht, The Netherlands. S.A.M.Gernaat@umcutrecht.nl.
P J HoNational University of Singapore, Saw Swee Hock School of Public Health, Singapore, 117549, Singapore.
N RijnbergDivision of Internal Medicine, Academic Medical Center, 1105 AZ, Amsterdam, The Netherlands.
M J EmausImaging Division, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
L M BaakUtrecht University, 3584 CX, Utrecht, The Netherlands.
M HartmanDepartment of Surgery, National University Hospital Singapore, Singapore, 119074, Singapore.
D E GrobbeeDepartment of Epidemiology, University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3584 CX, Utrecht, The Netherlands.
H M VerkooijenImaging Division, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
University Medical Center Utrecht · NLAcademic Medical Center · NLNational University Health System · SGNational University Hospital · SGUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer incidence and survival is high, which results in high prevalence of breast cancer survivors. The risk of (death from) cardiovascular disease (CVD) is higher in patients exposed to cardiotoxic treatments, in particular if they have pre-existing CVD risk factors. This study systematically summarized the risk of death from CVD following breast cancer.

methodsDatabases of Medline, Embase, and the Cochrane Library were systematically searched using the following terms and synonyms: breast cancer, cardiovascular disease, and cause of death. Articles reporting on both risk and risk factors of CVD mortality following breast cancer were eligible for inclusion. The methodological quality of each article was assessed using the Newcastle Ottawa quality assessment scale for cohort studies.

resultsFourteen articles were included assessing the risk of CVD mortality among 1,217,910 women with breast cancer. The methodological quality was high for the majority of the studies. Studies were heterogeneous in design, study population, length of follow-up, CVD outcomes, and risk factors. 1.6-10.4% of all women with breast cancer died of CVD. Women with breast cancer had a higher risk of CVD mortality than women from the general population. The risk of CVD mortality was higher among women with breast cancer with older age at diagnosis, left-sided tumor, diagnosis in an earlier calendar period, and black ethnic origin.

conclusionsCVD is an important cause of death following breast cancer. Identification of patients at high risk of CVD is important to optimize CVD prevention and tailor breast cancer treatment.

Indexed as

AgedBreast NeoplasmsCardiovascular DiseasesCohort StudiesFemaleHumansMiddle AgedRisk FactorsAbsolute riskBreast cancerCardiovascular diseaseRisk factors

Identifiers

PMID28503723
PMCPMC5495872
OpenAlexW2613080729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.